Please ensure Javascript is enabled for purposes of website accessibility

An FDA Letter Caused PTC Therapeutics to Crash Today

By Todd Campbell - Feb 23, 2016 at 12:26PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The FDA has issued a refuse-to-file letter on the Duchenne muscular dystrophy drug Translarna.


What: After the company received a "Dear John" letter from the Food and Drug Administration, shares in PTC Therapeutics (PTCT -0.92%) crashed 52% at 12:00 p.m. ET today.

So what: PTC Therapeutics markets the Duchenne muscular dystrophy drug Translarna in the EU, and patients have been hoping that DMD drugs like Translarna would similarly become available here in the United States.

However, PTC Therapeutics reported earlier today that the FDA has sent the company a "refuse-to-file" letter stating that Translarna's application for approval wasn't complete enough to permit a substantive review of the drug by the regulator.

The news throws cold water on any existing timeline for a potential Translarna launch in the U.S. and continues a string of bad news from the FDA for DMD drugs. In January, it opted against approving BioMarin's (BMRN -2.16%) drug Kyndrisa and sent notes to a key advisory committee that were harsh enough to have many anticipating an eventual FDA no-go for Sarepta Therapeutics' (SRPT -2.69%) DMD drug eteplirsen.

Now what: PTC Therapeutics says it's evaluating its options and that conceivably keeps the window open a crack for another filing. However, chances for any eventual approval could be hindered by arguably shaky efficacy in late-stage trials of Translarna that were reported in October.

Overall, the DMD market has an unquestionably massive need for new treatment options, but it appears the current generation of up-and-coming therapies just doesn't deliver the efficacy and safety necessary to pass muster with regulators. Given Translarna uncertain future, investors are right to head to the sidelines to await clarity.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

BioMarin Pharmaceutical Inc. Stock Quote
BioMarin Pharmaceutical Inc.
$83.25 (-2.16%) $-1.84
Sarepta Therapeutics, Inc. Stock Quote
Sarepta Therapeutics, Inc.
$74.25 (-2.69%) $-2.05
PTC Therapeutics, Inc. Stock Quote
PTC Therapeutics, Inc.
$39.68 (-0.92%) $0.37

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 06/28/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.